Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2022 Mar 3;12(1):3525.
doi: 10.1038/s41598-022-07395-x.

Effect of SGLT-2 inhibitor, empagliflozin, on blood pressure reduction in Chinese elderly hypertension patients with type 2 diabetes and its possible mechanisms

Lan Cheng  1 , Qianyu Fu  1 , Longhua Zhou  1 , Yuqin Fan  1 , Fenfen Liu  1 , Yuanyuan Fan  1 , Xin Zhang  1 , Weiqing Lin  1 , Xiaohe Wu  2
Affiliations
Randomized Controlled Trial

Effect of SGLT-2 inhibitor, empagliflozin, on blood pressure reduction in Chinese elderly hypertension patients with type 2 diabetes and its possible mechanisms

Lan Cheng et al. Sci Rep. .

Abstract

The current study evaluated the effect of SGLT-2 inhibitor, empagliflozin, on blood pressure reduction in Chinese elderly hypertension patients with type 2 diabetes and investigated its possible mechanisms. 124 patients were randomized to receive 25 mg empagliflozin QD, or placebo double blind for 12 weeks. Patients underwent 24-h ABPM. Endothelial function and arterial stiffness were also measured prior to randomization and at week 12. At week 12, adjusted mean difference versus placebo in change from baseline in mean 24-h SBP was - 8.14 mmHg (95% CI - 10.32, - 3.96, P = 0.005). At week 12, adjusted mean difference versus placebo in change from baseline in mean 24-h DBP was - 5.27 mmHg (95% CI - 8.19, - 1.35, P < 0.001). Changes in office BP were consistent with ABPM. Empagliflozin was well tolerated. Empagliflozin was associated with significant and clinically meaningful reductions in BP versus placebo in Chinese elderly patients with type 2 diabetes and hypertension. The underlying mechanisms possiblely at least in part were the improvements of endothelial function and arterial stiffness associated with empagliflozin.Registration number: ChiCTR2100054678, Registration date: December 23, 2021.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Hourly mean SBP (APBM) at week 12.
Figure 2
Figure 2
Hourly mean DBP (APBM) at week 12.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Apidechkul T. Prevalence and factors associated with type 2 diabetes mellitus and hypertension among the hill tribe elderly populations in northern Thailand. BMC Public Health. 2018;18(1):694. doi: 10.1186/s12889-018-5607-2. - DOI - PMC - PubMed
    1. Yashkin AP, Kravchenko J, Yashin AI, Sloan F. Mortality and macrovascular risk in elderly with hypertension and diabetes: Effect of intensive drug therapy. Am. J. Hypertens. 2018;31(2):220–227. doi: 10.1093/ajh/hpx151. - DOI - PMC - PubMed
    1. UK Prospective Diabetes Study Group Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317(7160):703–713. doi: 10.1136/bmj.317.7160.703. - DOI - PMC - PubMed
    1. Fox CS. Cardiovascular disease risk factors, type 2 diabetes mellitus, and the Framingham Heart Study. Trends Cardiovasc. Med. 2010;20(3):90–95. doi: 10.1016/j.tcm.2010.08.001. - DOI - PMC - PubMed
    1. Chen G, McAlister FA, Walker RL, Hemmelgarn BR, Campbell NR. Cardiovascular outcomes in framingham participants with diabetes: The importance of blood pressure. Hypertension. 2011;57(5):891–897. doi: 10.1161/HYPERTENSIONAHA.110.162446. - DOI - PMC - PubMed

Publication types

  NODES
chat 2
twitter 2